((自动化翻译由路透提供，请见免责声明 ))
9月30日 - ** 生物技术和医学研究公司IGM Biosciences 股价在延时交易中下跌21.4%至13美元
** 该公司称 (link)，今后将尽量减少用于二线转移性结直肠癌和其他肿瘤候选药物 aplitabart 的研究和临床开发的开支
** 公司任命业内资深人士玛丽-贝丝-哈勒（Mary Beth Harler）担任首席执行官，接替即将卸任首席执行官、总裁兼董事职务的弗雷德-施瓦泽（Fred Schwarzer）。
** 首席科学官 Bruce Keyt 也将辞去现有职务，继续担任顾问
** 公司医疗总监 Chris Takimoto 也将卸任
** 截至上一交易日收盘，公司股价已上涨近一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.